Table IV.
Assessment of non-hematological and hematological adverse events incidence during VTD therapy.
| Occurrence | |||
|---|---|---|---|
| Analyzed parameter | Yes (%) | No (%) | P-value |
| Polyneuropathy | |||
| Number of VTD cycles | |||
| ≥6 | 9.7 | 55.6 | >0.05 |
| <5 | 6.8 | 27.8 | |
| Duration of cycle | |||
| 21 days | 9.3 | 34.6 | >0.05 |
| 28 days | 7.3 | 48.8 | |
| Initial dose of thalidomide | |||
| 200 mg | 1.6 | 4.4 | >0.05 |
| 100 mg | 14.3 | 78.6 | |
| <100 mg | 0.55 | 0.55 | |
| Bortezomib dose reduction | |||
| Yes | 16.6 | 3.9 | <0.05 |
| No | 0.0 | 79.5 | |
| Infection | |||
| Number of VTD cycles | |||
| ≥6 | 2.9 | 62.4 | <0.05 |
| <5 | 2.0 | 32.7 | |
| Duration of cycle | |||
| 21 days | 2.9 | 41.0 | >0.05 |
| 28 days | 2.0 | 54.1 | |
| Initial dose of thalidomide | |||
| 200 mg | 0.0 | 11.0 | >0.05 |
| 100 mg | 4.0 | 165 | |
| <100 mg | 0.0 | 2.0 | |
| Bortezomib dose reduction | |||
| Yes | 2.0 | 18.5 | >0.05 |
| No | 2.9 | 76.6 | |
| Thrombosis | |||
| Number of VTD cycles | |||
| ≥6 | 2.9 | 62.4 | >0.05 |
| <5 | 1.0 | 33.7 | |
| Duration of cycle | |||
| 21 days | 2.0 | 41.9 | >0.05 |
| 28 days | 2.0 | 54.1 | |
| Initial dose of thalidomide | |||
| 200 mg | 0.6 | 5.5 | >0.05 |
| 100 mg | 1.6 | 91.2 | |
| <100 mg | 0.0 | 1.1 | |
| Bortezomib dose reduction | |||
| Yes | 1.5 | 19.0 | >0.05 |
| No | 2.4 | 77.1 | |
| Pulmonary embolism | |||
| Number of VTD cycles | |||
| ≥6 | 1.0 | 64.4 | >0.05 |
| <5 | 0.0 | 34.6 | |
| Duration of cycle | |||
| 21 days | 0.0 | 43.9 | >0.05 |
| 28 days | 1.0 | 55.1 | |
| Initial dose of thalidomide | |||
| 200 mg | 0.0 | 6.0 | >0.05 |
| 100 mg | 1.1 | 91.8 | |
| <100 mg | 0.0 | 1.1 | |
| Bortezomib dose reduction | |||
| Yes | 0.0 | 20.5 | >0.05 |
| No | 1.0 | 78.5 | |
| Constipations | |||
| Number of VTD cycles | |||
| ≥6 | 1.0 | 64.4 | >0.05 |
| <5 | 0.0 | 34.6 | |
| Duration of cycle | |||
| 21 days | 0.0 | 43.9 | >0.05 |
| 28 days | 1.0 | 55.1 | |
| Initial dose of thalidomide | |||
| 200 mg | 0.0 | 6.0 | >0.05 |
| 100 mg | 0.0 | 92.9 | |
| <100 mg | 0.0 | 1.1 | |
| Bortezomib dose reduction | |||
| Yes | 0.0 | 20.5 | >0.05 |
| No | 1.0 | 79.5 | |
| Skin alterations | |||
| Number of VTD cycles | |||
| ≥6 | 1.0 | 64.4 | >0.05 |
| <5 | 1.5 | 33.1 | |
| Duration of cycle | |||
| 21 days | 1.0 | 38.1 | >0.05 |
| 28 days | 1.5 | 54.6 | |
| Initial dose of thalidomide | |||
| 200 mg | 1.1 | 4.8 | >0.05 |
| 100 mg | 0.5 | 91.6 | |
| <100 mg | 0.0 | 0.0 | |
| Bortezomib dose reduction | |||
| Yes | 0.5 | 20.0 | >0.05 |
| No | 2.0 | 77.5 | |
| Neutropenia | |||
| Number of VTD cycles | |||
| ≥6 | 2.4 | 63.0 | >0.05 |
| <5 | 0.5 | 34.1 | |
| Duration of cycle | |||
| 21 days | 1.0 | 42.9 | >0.05 |
| 28 days | 2.0 | 54.1 | |
| Initial dose of thalidomide | |||
| 200 mg | 0.55 | 5.5 | >0.05 |
| 100 mg | 0.55 | 92.3 | |
| <100 mg | 0.0 | 1.1 | |
| Bortezomib dose reduction | |||
| Yes | 0.0 | 20.5 | >0.05 |
| No | 2.9 | 76.6 | |
| Thrombocytopenia | |||
| Number of VTD cycles | |||
| ≥6 | 0.5 | 64.9 | >0.05 |
| <5 | 1.5 | 33.2 | |
| Duration of cycle | |||
| 21 days | 2.0 | 41.9 | >0.05 |
| 28 days | 0.0 | 56.1 | |
| Initial dose of thalidomide | |||
| 200 mg | 1.1 | 4.9 | >0.05 |
| 100 mg | 0.6 | 92.3 | |
| <100 mg | 0.0 | 1.1 | |
| Bortezomib dose reduction | |||
| Yes | 0.5 | 20.0 | >0.05 |
| No | 1.5 | 78.0 | |
| Anemia | |||
| Number of VTD cycles | |||
| ≥6 | 2.9 | 62.4 | >0.05 |
| <5 | 2.9 | 31.8 | |
| Duration of cycle | |||
| 21 days | 4.4 | 39.5 | >0.05 |
| 28 days | 1.5 | 54.6 | |
| Initial dose of thalidomide | |||
| 200 mg | 3.3 | 2.7 | >0.05 |
| 100 mg | 1.1 | 91.8 | |
| <100 mg | 0.0 | 1.1 | |
| Bortezomib dose reduction | |||
| Yes | 1.5 | 19.0 | >0.05 |
| No | 4.4 | 75.1 | |
VTD, bortezomib, thalidomide, dexamethasone.